{"id":12763,"date":"2026-05-28T21:57:00","date_gmt":"2026-05-28T19:57:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=696a0dd55a1af20f9eabbc84d8795542"},"modified":"2026-05-28T21:57:00","modified_gmt":"2026-05-28T19:57:00","slug":"aahis-sla-se-adjuvant-technology-powers-lillys-acquisition-of-curevos-next-generation-shingles-vaccine","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=12763","title":{"rendered":"AAHI\u2019s SLA-SE Adjuvant Technology Powers Lilly\u2019s Acquisition of Curevo\u2019s Next-Generation Shingles Vaccine"},"content":{"rendered":"

\nSLA-SE adjuvant validated as a superior vaccine technology to protect people from infectious disease without debilitating side effects<\/b><\/p><\/a><\/a>

SEATTLE--(BUSINESS WIRE)--The Access to Advanced Health Institute (AAHI), a nonprofit biotech organization dedicated to developing vaccines and technologies for global health, today congratulates Eli Lilly and Company and Curevo Vaccine on Lilly\u2019s acquisition of Curevo.<\/p>

\nCurevo\u2019s lead asset, amezosvatein (CRV-101), is a Phase 3-ready subunit vaccine for the prevention of shingles (herpes zoster) that incorporates AAHI\u2019s proprietary SLA-SE adjuvant. The acquisition underscores the growing recognition of next-generation adjuvants that can deliver improved tolerability and strong immune responses.<\/p>

\n\u201cSLA-SE represents a significant advancement in adjuvant technology, designed to elicit robust T-cell immunity with a favorable safety profile,\u201d said Keeley Foley, CEO of AAHI. \u201cWe are thrilled that this technology, developed at AAHI, is now positioned to reach people through Lilly\u2019s world-class development and commercial capabilities.\u201d<\/p>

\nImportantly, AAHI retains rights to license and develop SLA-SE adjuvant for uses outside the shingles (varicella zoster virus) vaccine field. This includes in combination with other antigens for a wide range of infectious diseases, cancer vaccines, and additional indications.<\/p>

\nFor more information about AAHI and its work, visit www.aahi.org<\/a>.<\/p>

\nAbout Access to Advanced Health Institute (AAHI)<\/b><\/p>

\nAAHI is a Seattle-based nonprofit biotech research institute focused on translating high-impact science into affordable, effective, and accessible vaccines. With a global footprint including operations in the United States, England, and South Africa, AAHI collaborates with partners worldwide to combat infectious diseases and improve health equity. For more information, visit https:\/\/www.aahi.org\/<\/a> or contact us at https:\/\/www.aahi.org\/contact\/<\/a>.<\/p> Contacts<\/b>

\nMedia Contact:\nCasey Felipe, Director, Operations & Business Development\nAccess to Advanced Health Institute\nEmail: info@aahi.org<\/a>Phone: 206.381.0883<\/p>","protected":false},"excerpt":{"rendered":"

SLA-SE adjuvant validated as a superior vaccine technology to protect people from infectious disease without debilitating side effectsSEATTLE–(BUSINESS WIRE)–The Access to Advanced Health Institute (AAHI), a nonprofit biotech organization dedicated …<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-12763","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12763","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12763"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12763\/revisions"}],"predecessor-version":[{"id":12764,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/12763\/revisions\/12764"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12763"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12763"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12763"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}